Straits Times Index
3,331.70 +5.42 (+0.16%) S&P 500
5,469.30 +21.43 (+0.39%) Dow
39,112.16 -299.05 (-0.76%) Nasdaq
17,717.65 +220.84 (+1.26%) Bitcoin USD
61,403.00 +181.55 (+0.30%) CMC Crypto 200
1,273.75 -10.04 (-0.78%)
Cabaletta Bio, Inc. (CABA)
Pre-market:
| Previous close | 8.35 |
| Open | 8.27 |
| Bid | 7.19 x 700 |
| Ask | 7.26 x 200 |
| Day's range | 7.22 - 8.30 |
| 52-week range | 7.22 - 26.35 |
| Volume | |
| Avg. volume | 1,323,450 |
| Market cap | 348.798M |
| Beta (5Y monthly) | 2.47 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201
– No CRS, ICANS, infections or serious adverse events observed in either of the first two patients through data cut-off of May 28, 2024 – – CABA-201 exhibited anticipated profile of CAR T cell expansion and contraction with complete B cell depletion observed in both patients by day 15 post-infusion – – Improvements in both patients’ specific disease measures, consistent with academic experience of a similar 4-1BB CD19-CAR T, suggest emerging clinical benefit with CABA-201 while discontinuing all
- GlobeNewswire
Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference
PHILADELPHIA, May 29, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that Steven Nichtberger, M.D., Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024, at 11:00 a.m. ET in New York, NY. A live webcast of the
- GlobeNewswire
Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update
– No CRS or ICANS of any grade observed during the 28-day DLT observation window for either of the first patients dosed with CABA-201 in the RESET-Myositis™ and RESET-SLE™ trials – – Initial clinical data from each of the first patients in the RESET-Myositis and RESET-SLE trials to be presented at a satellite symposium at the EULAR 2024 Congress in June – – Evaluating CABA-201 without preconditioning by initiation of the RESET-PV™ sub-study within the ongoing DesCAARTes™ trial in pemphigus vulga
